<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515657</url>
  </required_header>
  <id_info>
    <org_study_id>PL-ASA-004</org_study_id>
    <nct_id>NCT01515657</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients</brief_title>
  <official_title>A Randomized, Actively Controlled, Crossover Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Patients With Type II Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PLx Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PLx Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine if aspirin from PL2200, an investigational product, gets into the
      blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether
      PL2200 is able to prevent blood clots as effectively as these other products, when
      administered to patients with diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to 99% Inhibition of Serum Thromboxane (TxB2)</measure>
    <time_frame>4 days</time_frame>
    <description>Aspirin's antiplatelet activity is measured by the capacity of platelets to generate serum thromboxane (a surrogate marker for inhibition of COX-1 by aspirin). Inhibition of serum thromboxane is a key marker of antiplatelet efficacy.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>PL2200 Aspirin Capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug arm; crossover design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immediate-Release Aspirin Tablets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator; crossover design</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enteric-coated aspirin caplets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active comparator; crossover design</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PL2200 Aspirin Capsules</intervention_name>
    <description>325 mg aspirin; once per day for 3 days</description>
    <arm_group_label>PL2200 Aspirin Capsules</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immediate-Release Aspirin Tablets</intervention_name>
    <description>325 mg aspirin; once per day for 3 days</description>
    <arm_group_label>Immediate-Release Aspirin Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enteric-coated aspirin caplets</intervention_name>
    <description>325 mg aspirin; once per day for 3 days</description>
    <arm_group_label>Enteric-coated aspirin caplets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 21-79

          -  Body mass index (BMI) of 30-40 kg/m2

          -  Non-insulin-dependent type-2 diabetics (as confirmed by hemoglobin A1c (HbA1c) of &gt;
             6.4% and/or fasting plasma glucose of &gt;125 mg/dL or current anti-diabetic medication)

          -  AA-induced platelet aggregation response of &gt;60% within 3 hours prior to initial dose
             of study drug administration

        Exclusion Criteria:

          -  Contraindications to aspirin

          -  Previous history of vascular disease

          -  Patient requires insulin

          -  Use of non-steroidal anti-inflammatory drugs, anti-secretory agents, antacids, and
             salicylate-containing nutritional supplements within 2 weeks of randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MedPace Clinical Pharmacology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2012</study_first_submitted>
  <study_first_submitted_qc>January 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <results_first_submitted>June 22, 2015</results_first_submitted>
  <results_first_submitted_qc>August 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 4, 2015</results_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PL2200 Aspirin First, Then IR Aspirin Tablets, Then EC Aspirin</title>
          <description>First Intervention Period:
PL2200 Aspirin Capsules: 325 mg aspirin; once per day for 3 days (after 2-week washout period)
Second Intervention Period:
IR (immediate-release) aspirin tablets: 325 mg aspirin; once per day for 3 days (after 2-week washout period)
Third Intervention Period:
EC (enteric coated) aspirin: 325 mg aspirin; once per day for 3 days</description>
        </group>
        <group group_id="P2">
          <title>IR Aspirin Tablets First, Then EC Aspirin, Then PL2200 Aspirin</title>
          <description>First Intervention Period:
IR (immediate-release) aspirin tablets: 325 mg aspirin; once per day for 3 days (after 2-week washout period)
Second Intervention Period:
EC (enteric coated) aspirin: 325 mg aspirin; once per day for 3 days (after 2-week washout period)
Third Intervention Period:
PL2200 Aspirin Capsules: 325 mg aspirin; once per day for 3 days</description>
        </group>
        <group group_id="P3">
          <title>EC Aspirin First, Then PL2200 Aspirin, Then IR Aspirin Tablets</title>
          <description>First Intervention Period:
EC (enteric coated) aspirin: 325 mg aspirin; once per day for 3 days (after 2-week washout period)
Second Intervention Period:
PL2200 Aspirin Capsules: 325 mg aspirin; once per day for 3 days (after 2-week washout period)
Third Intervention Period:
IR (immediate-release) aspirin tablets: 325 mg aspirin; once per day for 3 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All patients that received at least 1 dose of study drug under the study protocol.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="10.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to 99% Inhibition of Serum Thromboxane (TxB2)</title>
        <description>Aspirin's antiplatelet activity is measured by the capacity of platelets to generate serum thromboxane (a surrogate marker for inhibition of COX-1 by aspirin). Inhibition of serum thromboxane is a key marker of antiplatelet efficacy.</description>
        <time_frame>4 days</time_frame>
        <population>Pharmacodynamic (PD) Evaluable Population for Time to 99% Inhibition</population>
        <group_list>
          <group group_id="O1">
            <title>PL2200 Aspirin Capsules</title>
            <description>Investigational drug arm; crossover design
PL2200 Aspirin Capsules: 325 mg aspirin; once per day for 3 days</description>
          </group>
          <group group_id="O2">
            <title>Immediate-Release Aspirin Tablets</title>
            <description>Active comparator; crossover design
Immediate-Release Aspirin Tablets: 325 mg aspirin; once per day for 3 days</description>
          </group>
          <group group_id="O3">
            <title>Enteric-coated Aspirin Caplets</title>
            <description>Active comparator; crossover design
Enteric-coated aspirin caplets: 325 mg aspirin; once per day for 3 days</description>
          </group>
        </group_list>
        <measure>
          <title>Time to 99% Inhibition of Serum Thromboxane (TxB2)</title>
          <description>Aspirin's antiplatelet activity is measured by the capacity of platelets to generate serum thromboxane (a surrogate marker for inhibition of COX-1 by aspirin). Inhibition of serum thromboxane is a key marker of antiplatelet efficacy.</description>
          <population>Pharmacodynamic (PD) Evaluable Population for Time to 99% Inhibition</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.36" spread="23.42"/>
                    <measurement group_id="O2" value="16.65" spread="27.21"/>
                    <measurement group_id="O3" value="48.64" spread="31.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>modified Intent-to-Treat population: all patients that received at least 1 dose of study drug under the study protocol</desc>
      <group_list>
        <group group_id="E1">
          <title>PL2200 Aspirin Capsules</title>
          <description>Investigational drug arm; crossover design
PL2200 Aspirin Capsules: 325 mg aspirin; once per day for 3 days</description>
        </group>
        <group group_id="E2">
          <title>Immediate-Release Aspirin Tablets</title>
          <description>Active comparator; crossover design
Immediate-Release Aspirin Tablets: 325 mg aspirin; once per day for 3 days</description>
        </group>
        <group group_id="E3">
          <title>Enteric-coated Aspirin Caplets</title>
          <description>Active comparator; crossover design
Enteric-coated aspirin caplets: 325 mg aspirin; once per day for 3 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Standard confidentiality agreement</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ronald Zimmerman</name_or_title>
      <organization>PLx Pharma</organization>
      <phone>1-713-842-1249 ext 205</phone>
      <email>ron.zimmerman@plxpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

